- Details
- (Length of Presentation: 8 min) The 68Ga-PSMA PET/CT has a high clinical impact for preoperative staging, restaging biochemical recurrence after radical prostatectomy, and treatment monitoring. Dr. Chen highlights the details of this trial with two objectives. They assessed 68 Ga-PSMA PET/CT in primary prostate cancer with different clinical risks and further studied the inclusion of 11 C-Acetate...
|
- Details
- (Length of Interview: 20 min) John Feller is interviewed by John Fortin on laser focal therapy and focal laser ablation (FLA) therapy for the treatment in prostate cancer. He fields questions including his opinion on the typical candidate, availability and measuring side effects in FLA therapy. In addition, future plans to expand the scope in terms of the number of sites offering this therapy and...
|
- Details
- (Length of Presentation: 8 min) This presentation represents a study performed to assess if [18F]FDHT PET/CT could be a valuable imaging biomarker in patients with prostate cancer. Biographies: Gem Kramer, Radiology and Nuclear Medicine VU University Medical Center Amsterdam the Netherlands Read the Full Video Transcript {article title="assessment-of-simplified-methods-for-quantification-of-18f-fd...
|
- Details
- (Length of Discussion: 13 min) Todd Morgan shares the unique program that he and his GU team at the University of Michigan have implemented in an effort to gain a better understanding of the genetics and genomics involved with progression in prostate cancer. Biographies: Todd M. Morgan, M.D. is a urological surgeon specializing in the treatment of genitourinary malignancies and an Associate Profes...
|
- Details
- ( Length of Presentation 7 minutes) Christoph Rischpler presents a study aimed at investigating the PSMA-ligand uptake in PET in cervical, coeliac and sacral ganglia as a pitfall for lymph node metastases in prostate cancer imaging. This patient population consisted of 308 randomly selected patients who underwent Gallium 68 PSMA-PET between October 2012 and March 2014. For image analysis, they det...
|
- Details
- (Length of Discussion: 20 min) Alicia Morgans and David Penson discuss the relevance of Prostate Cancer Awareness Month and the importance of elevating the awareness for men and their respective caregivers about prostate cancer and other men's health issues and the need to be screened routinely for prostate cancer. Biographies: David F. Penson, MD, MPH, is the Paul V. Hamilton, M.D. and Virginia E...
|
- Details
- (Length of Discussion: 17 min) Alicia Morgans and Matt Cooperberg discuss the controversial topic of how to optimally screen for prostate cancer based on the final recommendations from the U.S. Preventive Services Task Force. Biographies: Matthew Cooperberg, MD, MPH, FACS, UCSF Helen Diller Family Comprehensive Cancer Center Alicia Morgans, MD, MPH Further Related Content: Biomarker Debate: Adopt,...
|
- Details
- (Length of Discussion: 24 min) Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Biographies: Daniel Spratt, MD, Assistant Professor, Vice Chair, Clinical Research Chair, Division of Genitourinary Clinical Research Chief, Genitourinary Radiotherapy Program Department of Radiation Oncology, University of Michig...
|
- Details
- (Length of Discussion: 4 min) Dr. Sanford J. Siegel, CEO of Chesapeake Urology, has always been an advocate and supporter of prostate cancer screening in men, especially those at high risk. Since 2006, under his leadership, Chesapeake Urology has provided free screenings to Maryland men, mostly in Baltimore City. In this video, Dr. Siegel shares his own prostate cancer story. Biographies: Sanford...
|
- Details
- (Length of Presentation: 20 min) Neal Shore, MD, FACS interviews E. David Crawford on a forthcoming paper he authored titled, A ndrogen Receptor–Targeted Treatments for Prostate Cancer: 35 Years’ Progress with Anti-androgens . This paper takes the historical approach in reviewing the treatment of prostate cancer, where we started in the 60's, where we are today and where we hope to be in the futur...
|
